Brigitte Chabert-Bernard
Reims, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
COVID-19 and chronic liver disease: results from the 1219 patients French registry.
Journal: Scientific reports
Published: July 25, 2024
Association between the dietary inflammatory index and the risk of hepatocellular carcinoma in a cirrhotic population.
Journal: Clinical nutrition (Edinburgh, Scotland)
Published: April 22, 2024
ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 27, 2021
Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
Journal: Clinics and research in hepatology and gastroenterology
Published: June 30, 2020
Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients.
Journal: Alimentary pharmacology & therapeutics
Published: January 06, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
Journal: Journal of hepatology
Published: November 17, 2019
Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study.
Journal: Digestive diseases and sciences
Published: August 30, 2019
General practitioner density is not associated with survival in patients with hepatocellular carcinoma
Journal: Sante publique (Vandoeuvre-les-Nancy, France)
Published: February 16, 2019
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Journal: Gastroenterology
Published: April 07, 2018
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Journal: Gastroenterology
Published: March 30, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
Journal: Kidney international
Published: November 17, 2017
Last Updated: 09/26/2026